(Q38034816)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Mechanisms of acquired resistance to targeted cancer therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Timothy R Wilson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Jeff Settleman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

0 references

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

999-1014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

11 February 2020

cites work

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

21 January 2018

1 reference

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

c-MET as a potential therapeutic target and biomarker in cancer

21 January 2018

1 reference

Discovery of a novel B-Raf fusion protein related to c-Met drug resistance

21 January 2018

1 reference

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

21 January 2018

1 reference

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients

21 January 2018

1 reference

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

p95HER2 and breast cancer

21 January 2018

1 reference

Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients

21 January 2018

1 reference

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

21 January 2018

1 reference

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

21 January 2018

1 reference

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer

21 January 2018

1 reference

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

21 January 2018

1 reference

Mutation-driven drug development in melanoma

21 January 2018

1 reference

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

21 January 2018

1 reference

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation

21 January 2018

1 reference

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

21 January 2018

1 reference

ERK inhibition overcomes acquired resistance to MEK inhibitors.

21 January 2018

1 reference

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

21 January 2018

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms

21 January 2018

1 reference

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

21 January 2018

1 reference

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

21 January 2018

1 reference

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

21 January 2018

1 reference

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

21 January 2018

1 reference

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance

21 January 2018

1 reference

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.

21 January 2018

1 reference

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

21 January 2018

1 reference

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

21 January 2018

1 reference

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib

21 January 2018

1 reference

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance

21 January 2018

1 reference

Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases

21 January 2018

1 reference

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

21 January 2018

1 reference

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors

21 January 2018

1 reference

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

21 January 2018

1 reference

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer

21 January 2018

1 reference

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

21 January 2018

1 reference

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

21 January 2018

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

Targeting the androgen receptor pathway in prostate cancer

21 January 2018

1 reference

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

Alternatively spliced androgen receptor variants

21 January 2018

1 reference

The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

21 January 2018

1 reference

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer

21 January 2018

1 reference

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

21 January 2018

1 reference

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

21 January 2018

1 reference

Inhibition of PI3K and MEK: it is all about combinations and biomarkers

21 January 2018

1 reference

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

21 January 2018

1 reference

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

21 January 2018

1 reference

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

21 January 2018

1 reference

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

21 January 2018

1 reference

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

21 January 2018

1 reference

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth

21 January 2018

1 reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

21 January 2018

1 reference

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

21 January 2018

1 reference

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state

21 January 2018

1 reference

Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized

21 January 2018

1 reference

Slug and Sox9 cooperatively determine the mammary stem cell state

21 January 2018

1 reference

Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?

21 January 2018

1 reference

The epithelial-mesenchymal transition generates cells with properties of stem cells

21 January 2018

1 reference

Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.12.86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22894672%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference